Sterile Tubing Welder Market Size, Trends, Share, Growth | Report 2022-2030
The global sterile tubing welder market was valued at USD 2.3 billion in 2021 and it is predicted to surpass around USD 3.6 billion by 2030 with a CAGR of 5.1% from 2022 to 2030.
Increasing demand for blood, blood products, and biopharmaceutical products is anticipated to drive the market for sterile tubing welder.
Blood transfusion is one of the frequently performed medical procedures. Severe road traffic injuries, major surgical procedures, and hematology diseases, such as thalassemia, anemia, and leukemia, are some of the key reasons for the transfusion procedure. According to the Association for Safe International Road Travel (ASIRT) article, nearly 20 to 50 million individuals are injured or disabled in road accidents. Thus, high cases of road traffic injuries are anticipated to fuel sterile tubing welder market growth.
Wastage of collected blood due to contamination, blood bag leakages, improper storage, and lack of proper handling facilities and qualified professionals are anticipated to increase the demand for innovative and medically advanced sterile instruments, such as automated sterile tubing welders. For instance, in India, nearly 10% of blood components and around 71% of whole blood are wasted each year due to the above-stated reasons.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 2.3 billion |
| Revenue Forecast by 2030 | USD 3.6 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.1% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Mode, application, end-use, region |
| Companies Covered | Sartorius Stedim Biotech S.A.; Terumo BCT Inc.; GE Healthcare; MGA technologies; VANTE Biopharm; Genesis BPS; Biomen Biosystems Company Ltd.; Flex Concepts Inc.; and Shanghai Le Pure Biological Technology Co., Ltd. |
Mode Insights
On the basis of modes, the global market has been further categorized into manual and automatic. In 2021, the automatic welder segment dominated the global market and accounted for more than 83.0% of the overall revenue share. The segment is anticipated to retain its leading position throughout the forecast period owing to the improved weld quality and user-friendliness of these welding machines. Automatic welding machines enable the setting up of weld speed and time without requiring a highly trained professional and the relatively higher weld speed of the device outpaces a skilled welder, thereby reducing the dependency on human labor. Thus, increased output and reduced labor costs are anticipated to increase the demand for these devices.
Manual sterile tubing welders typically require skilled professionals who are aware of safety protocols and current good manufacturing practices. These jobs require knowledge-specific skills and lack of knowledge on how to operate the devices could result in risk of contamination. Thus, a lack of skilled professionals can limit market growth. Comparatively, automated devices reduce weld & operator time, lower scrap & labor costs, offer good weld quality, and are easy to use. The automatic machines also have temperature monitoring sensors and blade controllers that help yield better results. These benefits of automatic devices are anticipated to fuel their demand.
Application Insights
On the basis of applications, the global market has been segmented into biopharmaceutical, blood processing, diagnostic laboratories, and others. The blood processing segment dominated the global market in 2021 and accounted for the largest revenue share of more than 61.00%. The segment is anticipated to witness lucrative growth over the forecast period. Increasing demand for blood & blood products is anticipated to be the key driver for the segment. This can be attributed to the high demand for personalized medicine, cell & gene therapies, and the high prevalence of blood disorders, such as hemophilia. For instance, hemophilia is estimated to affect nearly 1,125,000 men across the globe.
Hospitals are adopting sophisticated devices to reduce patient turnaround time and meet the increasing demand. The use of complex sophisticated devices has, in turn, led hospitals to reevaluate sterile processing departments and equipment to meet the infection control standard. Furthermore, the presence of transfusion committees in hospitals is anticipated to ensure the use of sterile equipment for quality transfusions and patient safety. According to the WHO, transfusion committees are present in nearly 68% of European, 40% of South Pacific, 57% of Eastern Mediterranean, 17% of the Americas, 79% of Southeast Asian, and 12 % of African hospitals. Based on these statistics, it is estimated that the needs will increase over the forecast period, hence hospitals are also expected to witness lucrative growth rates from 2022 to 2030.
End-use Insights
On the basis of end-uses, the global market is further categorized into hospitals, research clinics, blood centers, and others. The hospitals segment dominated the global market in 2021 and accounted for the maximum share of more than 41.00% of the overall revenue. The segment is anticipated to grow lucratively over the forecast period on account of the presence of various advanced hematology-related equipment in hospital settings. In addition, the availability of a range of wide treatment options in hospital facilities has also increased the number of visits for diagnosis and treatment of blood disorders in these facilities.
Blood centers are also anticipated to witness a substantial growth rate during the forecast period. This can be attributed to an increase in the demand for blood & blood products for the treatment of various blood disorders, such as leukemia, thalassemia, severe anemia, and others. In addition, an increase in the cases of road accidents across the globe is anticipated to augment the demand for blood & blood products. Thich, in turn, is also estimated to facilitate the growth of the global market during the forecast period.
Regional Insights
North America dominated the global market in 2021 and accounted for more than 38.5% of the global revenue share in the same year. An increase in the prevalence of chronic diseases, recent technological advancements, and high demand for hygienic & sterile environments to avoid contamination are some of the major factors contributing to the growth of the market in this region. The growing burden of chronic diseases in the U.S. is one of the key factors boosting the market growth. According to the National Health Council 2020 report, about 157 million individuals are estimated to have at least one chronic condition.
It is also estimated that 7 out of 10 deaths occur due to a chronic illness with kidney failure as one of the major conditions in the U.S. The Asia Pacific region is expected to grow at a rapid pace over the forecast period. An increase in the number of major multinational companies investing in research & development in this region has proved to be a major factor driving the growth of the pharmaceutical & biopharmaceutical industries. In addition, a rise in the geriatric population and presence of a large fraction of the population belonging to middle-income group significantly increases the demand for innovative & cost-effective sterile tubing welder devices to attract key medical device companies within the region.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Sterile Tubing Welder Market
5.1. COVID-19 Landscape: Sterile Tubing Welder Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Sterile Tubing Welder Market, By Mode
8.1. Sterile Tubing Welder Market, by Mode, 2022-2030
8.1.1 Manual
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Automatic
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Sterile Tubing Welder Market, By Application
9.1. Sterile Tubing Welder Market, by Application, 2022-2030
9.1.1. Biopharmaceutical
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Blood Processing
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Diagnostic Laboratories
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Sterile Tubing Welder Market, By End-use
10.1. Sterile Tubing Welder Market, by End-use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Blood Centers
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Sterile Tubing Welder Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Mode (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Mode (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Mode (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Mode (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Mode (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Mode (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Mode (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Mode (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Mode (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Mode (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Mode (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Sartorius Stedim Biotech S.A.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Terumo BCT Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. GE Healthcare
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. MGA technologies
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. VANTE Biopharm
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Genesis BPS
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biomen Biosystems Company Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Flex Concepts Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Shanghai Le Pure Biological Technology Co., Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers